October 22, 2025 a 11:43 am
ABBV: Fundamental Ratio Analysis - AbbVie Inc.
AbbVie Inc. remains a pivotal player in the pharmaceutical industry with a diverse product portfolio. Although its current fundamentals, indicated by a rating of C+, suggest room for improvement, its significant research collaborations and product lineup present potential for growth. Investors should consider both opportunities and risks when evaluating AbbVie's stock potential.
Fundamental Rating
The current fundamental ratings for AbbVie Inc. indicate areas of strength and those requiring attention. The overall rating is a C+.
| Category | Score | Visual |
|---|---|---|
| Discounted Cash Flow | 5 | |
| Return on Equity | 1 | |
| Return on Assets | 4 | |
| Debt to Equity | 1 | |
| Price to Earnings | 1 | |
| Price to Book | 1 |
Historical Rating
The historical ratings provide insight into how AbbVie's evaluation has evolved over time.
| Date | Overall Score | DCF | ROE | ROA | Debt/Equity | P/E | P/B |
|---|---|---|---|---|---|---|---|
| 2025-10-21 | 2 | 5 | 1 | 4 | 1 | 1 | 1 |
| Previous Recorded | 0 | 5 | 1 | 4 | 1 | 1 | 1 |
Analyst Price Targets
The analyst price targets provide a range of expectations for AbbVie's stock performance.
| High | Low | Median | Consensus |
|---|---|---|---|
| 284 | 225 | 250 | 250.33 |
Analyst Sentiment
The analyst sentiment towards AbbVie highlights a predominantly positive outlook.
| Recommendation | Count | Visual |
|---|---|---|
| Strong Buy | 0 | |
| Buy | 25 | |
| Hold | 13 | |
| Sell | 1 | |
| Strong Sell | 0 |
Conclusion
AbbVie Inc.'s substantial portfolio and strategic collaborations bode well for future growth, despite some fundamental challenges. The company's current analyst sentiment reflects a strong bias towards buying, though investors should carefully weigh this against its historical performance and current financial indicators. Overall, AbbVie's strong market presence in healthcare poses promising potential, albeit necessitating vigilant oversight of its financial strategies.